Humans Male *Urinary Bladder Neoplasms Reproducibility of Results ROC Curve Image Interpretation Computer-Assisted Muscles Magnetic Resonance Imaging Retrospective Studies Bladder cancer Inter-reader agreement Meta-analysis Reliability Vi-rads

Administration Intravesical *Carcinoma Transitional Cell/pathology Humans Male Neoplasm Invasiveness/pathology Neoplasm Recurrence Local/pathology Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/therapy

Cystectomy France Humans Lymphatic Irradiation Palliative Care Patient Positioning Radiation Oncology Radiotherapy Dosage Radiotherapy Adjuvant Radiotherapy Conformal Urinary Bladder Neoplasms/diagnostic imaging/pathology/*radiotherapy/surgery Bladder cancer Cancers de la vessie Chemoradiation Chimioradiothérapie French society for radiation oncology Guidelines Radiation therapy Radiothérapie Recommandations Société française de radiothérapie oncologique

Data Systems Humans Magnetic Resonance Imaging/methods *Multiparametric Magnetic Resonance Imaging Muscles Retrospective Studies *Urinary Bladder Neoplasms/diagnostic imaging Diffusion magnetic resonance imaging Neoplasm grading Radiographic image enhancement Urinary bladder neoplasms Urologic surgical procedures

Diffusion Magnetic Resonance Imaging Humans Magnetic Resonance Imaging/methods Muscles Sensitivity and Specificity Urinary Bladder/diagnostic imaging/pathology *Urinary Bladder Neoplasms/diagnostic imaging/pathology Vesical Imaging-Reporting and Data System multiparametric magnetic resonance imagine muscle-invasive bladder cancer staging urothelial carcinoma

Carcinoma Transitional Cell/pathology Disease-Free Survival Humans *Neoplasm Staging Prognosis Urinary Bladder/*pathology Urinary Bladder Neoplasms/*pathology Bladder urothelial carcinoma Meta-analysis Squamous differentiation

Combined Modality Therapy Humans Light Narrow Band Imaging *Urinary Bladder Neoplasms/diagnostic imaging/surgery cystoscopy recurrence urinary bladder neoplasms

Humans Neoplasm Staging Retrospective Studies Sensitivity and Specificity Ultrasonography *Urinary Bladder Neoplasms/diagnostic imaging

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Cystoscopy/*methods Feasibility Studies Humans Liquid Biopsy/methods Sensitivity and Specificity *Spectrum Analysis Raman Urinary Bladder/diagnostic imaging/*pathology Urinary Bladder Neoplasms/*diagnosis/pathology/urine Urine/cytology Bladder cancer Raman spectroscopy diagnosis meta-analysis optical

5-aminolaevulinic acid cystectomy cystoscopy hexylaminolaevulinate narrow-band imaging photodynamic diagnosis commercial or financial relationships that could be construed as a potential conflict of interest.

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant/methods Cisplatin/therapeutic use Clinical Decision-Making/methods *Cystectomy Disease-Free Survival Female Humans Male Neoadjuvant Therapy/methods Neoplasm Recurrence Local/*epidemiology/pathology/prevention & control Neoplasm Staging Patient Selection *Sex Factors Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/pathology/*therapy Adjuvant chemotherapy Bladder cancer Gender Meta-analysis Neoadjuvant chemotherapy

Carcinoma Transitional Cell/*diagnostic imaging/*pathology Humans *Multiparametric Magnetic Resonance Imaging Neoplasm Staging/methods Reproducibility of Results Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnostic imaging/*pathology

Data Systems Humans *Multiparametric Magnetic Resonance Imaging Neoplasm Invasiveness Predictive Value of Tests Reproducibility of Results Urinary Bladder Neoplasms/*diagnostic imaging/pathology Bladder cancer Magnetic resonance imaging Meta-analysis Muscle invasive Systematic review Vesical Imaging Reporting and Data System

Cystectomy Humans Neoplasm Recurrence Local/surgery Prospective Studies *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures bladder cancer repeat restaging second look transurethral resection

Disease Progression Humans Muscle Smooth/pathology Neoplasm Grading Neoplasm Invasiveness Neoplasm Staging Treatment Failure Urinary Bladder/pathology Urinary Bladder Neoplasms/*pathology/*therapy *Watchful Waiting Active surveillance Non-Muscle Invasive bladder cancer Urothelial neoplasm

*Carcinoma Transitional Cell Evidence-Based Medicine Humans *Radiology Societies Medical United States *Urinary Bladder Neoplasms/diagnostic imaging Auc Appropriate Use Criteria Appropriateness Criteria Bladder cancer Muscle invasive bladder cancer Nonmuscle invasive bladder cancer Surveillance Transitional cell carcinoma Urothelial cancer

Carcinoma Transitional Cell/epidemiology/*pathology Disease Progression Humans Neoplasm Invasiveness Neoplasm Recurrence Local/epidemiology Neoplasm Staging Prognosis Urinary Bladder Neoplasms/epidemiology/*pathology Bladder cancer Progression Staging Substage T1 Urothelial carcinoma pT1

Vi-rads bladder cancer bladder cancer staging inter-reader agreement multiparametric magnetic resonance imaging muscle-invasive bladder cancer

5-ala 5-aminolaevulinic acid Hal Pdd accuracy meta-analysis bladder cancer blue light cystoscopy cystoscopy hexaminolevulinate narrow band imaging photodynamic diagnosis fluorescence consultant for Janssen Ferring Photocure Taris Spectrum Pacific Edge QED Abbvie Johnson & Johnson Seattle Genetics Nucleix Aduro and BMS. Ashish Kamat is is a consultant for Photocure. Mihir Desai is a consultant for Procept Biorobotics and Auris Surgical. Yair Lotan is a consultant for Photocure. Angela Smith is an investigator for Urogen and a consultant for FerGene Urogen and Merck.